Summit Therapeutics (SMMT)
(Delayed Data from NSDQ)
$3.86 USD
+0.31 (8.73%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.86 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Income Statements
Fiscal Year end for Summit Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 1 | 2 | 1 | 1 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1 | 2 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 610 | 73 | 88 | 54 | 28 |
Income After Depreciation & Amortization | -610 | -72 | -86 | -53 | -27 |
Non-Operating Income | -5 | -7 | -2 | 0 | -2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -615 | -79 | -89 | -53 | -29 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -615 | -79 | -89 | -53 | -29 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -615 | -79 | -89 | -53 | -29 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -608 | -70 | -84 | -51 | -26 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 2 | 2 | 2 |
Income After Depreciation & Amortization | -610 | -72 | -86 | -53 | -27 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 621.11 | 192.15 | 92.29 | 69.34 | NA |
Diluted EPS Before Non-Recurring Items | -0.15 | -0.41 | -0.96 | -0.75 | NA |
Diluted Net EPS (GAAP) | -0.99 | -0.41 | -0.96 | -0.76 | NA |
Fiscal Year end for Summit Therapeutics PLC falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 36.21 | 20.49 | 15.79 | 537.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -36.21 | -20.49 | -15.79 | -537.16 |
Non-Operating Income | NA | -0.36 | -0.78 | 1.08 | -5.22 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -36.57 | -21.27 | -14.72 | -542.38 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -36.57 | -21.27 | -14.72 | -542.38 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -36.57 | -21.27 | -14.72 | -542.38 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 732.00 | 708.93 | 735.85 | 379.28 |
Diluted EPS Before Non-Recurring Items | NA | -0.05 | -0.03 | -0.02 | -0.06 |
Diluted Net EPS (GAAP) | NA | 0.49 | -0.03 | -0.02 | -1.43 |